Life Sciences & Biotechnology
Title : | Novel beta3-adrenergic agonists as senolytics and insulin sensitizers: studies in adipose tissue of metabolic dyshomeostasis model systems |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Endocrinology, diabetology, metabolomics |
Principal Investigator : | Dr. Anil Nilkanth Gaikwad, CsIR-Central Drug Research Institute, Lucknow, Uttar Pradesh |
Timeline Start Year : | 2024 |
Timeline End Year : | 2027 |
Contact info : | anil_gaikwad@cdri.res.in |
Details
Executive Summary : | India has become the world's diabetic hub, with 74.2 million patients and expected to reach 124.8 million by 2045. Diabetes and obesity are emerging global health challenges, with metabolic disorders linked to chronic low-grade inflammation. Adipose tissue plays a crucial role in glucose, lipid, and energy homeostasis. Aging is correlated with increased prevalence of diabetes, cardiovascular diseases, and dyslipidemia. Adipose tissue senescence is a major contributor to obesity and age-associated metabolic disorders. The research aims to develop and characterize a chronic hyper-insulinemia induced insulin resistance model in 3T3-L1 and hMsC derived adipocytes and their effects on senescence pathways in in vivo tissue levels. Elevated glucose and lipid levels cause inflammation and accumulation of senescent cells in adipose tissue. Increasing healthy lifespan can decrease adipose senescence. beta3 adrenergic receptor agonists are proposed as potential senolytics to eliminate senescent cells. This project will open new avenues for generating therapies for age-associated metabolic disorders. |
Co-PI: | Dr. sashidhara V Koneni, CsIR-Central Drug Research Institute, Lucknow, Uttar Pradesh |
Total Budget (INR): | 49,83,560 |
Organizations involved